Trivalent Therapeutics is an early, patent-stage company exploring whether combining an incretin (GLP-1-class) agonist with an opioid antagonist could address Alcohol Use Disorder through two complementary mechanisms. This is a research hypothesis — not an approved product, and not a granted patent.
A single-founder, IP-focused company at the concept stage.
Trivalent Therapeutics Inc. is a Delaware C-Corporation based in Dover, Delaware. The company is at the intellectual-property stage and does not conduct clinical development. It has no marketed products and no approved therapies.
Method-of-use patent applications covering the combination of an incretin agonist with naltrexone for Alcohol Use Disorder. Our filed provisional leads with the FDA-approved agent tirzepatide and covers a broader glucagon-receptor-active co-agonist class (e.g., retatrutide, pemvidutide). These incretins are not our compounds; any rights we may obtain would be method-of-use rights only.
A reasonable, unproven hypothesis about two reinforcement pathways in AUD.
Naltrexone, an approved opioid antagonist, blunts the opioid-mediated reward of alcohol. Its efficacy in AUD is well established.
GLP-1-class agonists show growing evidence of reducing alcohol consumption. Multi-target incretins — tirzepatide (GLP-1/GIP) and glucagon-receptor-active co-agonists — may contribute additional effects, which we hypothesize but have not tested for our specific combinations.
Applications on file. Nothing granted.
We hold a provisional application (No. 64/110,198, filed July 13, 2026) and an earlier pending nonprovisional application (No. 19/705,839). No patent has been granted. A provisional secures a priority date only; whether any claims will ever issue, and how broadly, is uncertain and subject to examination. These are method-of-use applications covering combinations that use other companies' molecules.
The provisional broadens the position to a glucagon-receptor-active incretin co-agonist class (e.g., retatrutide, pemvidutide) combined with an opioid antagonist, and adds a lead embodiment pairing the FDA-approved agent tirzepatide with naltrexone.
We describe this space accurately, including where others are ahead of us.
| Program / reference | What it is | Status in AUD |
|---|---|---|
| Eli Lilly — brenipatide (LY3537031) | GLP-1/GIP agonist | Phase 3 AUD trials (RENEW-ALC-1/2) |
| Altimmune — pemvidutide | GLP-1/glucagon (GCGR) agonist | Phase 2 AUD (RECLAIM); FDA Fast Track |
| Semaglutide (GLP-1) | GLP-1 agonist | Human AUD signals; EHR evidence |
| US 2015/0038417 A1 (Novo Nordisk) | Prior-art application | Withdrawn; published disclosure covers GLP-1 agonist + naltrexone for alcoholism |
| Trivalent (this company) | Incretin (incl. tirzepatide / glucagon co-agonists) + naltrexone method | Provisional filed (2026) + pending application; concept stage; no data |
We are seeking a development or licensing partner for this AUD combination IP.
Trivalent's intellectual property is a method-of-use position; the Company is not a clinical developer. We are open to option, license, or research-collaboration discussions with pharmaceutical companies and specialty-pharma or IP groups positioned to develop or clear the combination — most naturally parties already working with incretin agonists in metabolic disease or addiction.
Download the non-confidential summary (PDF)
Partnership & licensing inquiries: contact@trivalent-therapeutics-inc.com
For scientific, partnership, or general inquiries, contact:
Business Development
Trivalent Therapeutics Inc., 8 The Green, Suite A, Dover, DE 19901
